Anti-leukemic activity of axitinib against cells harboring the BCR-ABL T315I point mutation

Journal of Hematology & Oncology

Kazuma Ohyashiki¹  Juri Sakuta¹  Yuko Tanaka¹  Tetsuzo Tauchi¹  Seiichi Okabe¹ 

[1] Department of Hematology, Tokyo Medical University, 6-7-1 Nishi-shinjuku, Shinjuku-ku 160-0023, Tokyo, Japan

关键词: Compound mutation;    T315I;    Ponatinib;    Resistant cell;    Axitinib;   

Others  :  1222641
DOI  :  10.1186/s13045-015-0190-9

 received in 2015-07-07, accepted in 2015-07-17,  发布年份 2015

【 摘 要 】

The BCR-ABL; breakpoint cluster region-Abelson point mutation T315I is resistant to ABL tyrosine kinase inhibitors. However, axitinib, a vascular endothelial growth factor receptor inhibitor, is effective against this mutation. In this study, we investigated axitinib activity against ponatinib-resistant cells and found that axitinib inhibited cellular growth and apoptosis in Ba/F3 T315I-mutant cells and T315I-mutant primary samples, but not in ponatinib-resistant Ba/F3 cells and primary samples. Thus, an alternative strategy may be required to improve the prognosis of Philadelphia-chromosome-positive leukemia patients harboring BCR-ABL point mutations.

【 授权许可】

   
2015 Okabe et al.

【 图 表 】

Fig. 1.

【 参考文献 】

• [1]Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973; 243:290-293.
• [2]Kurzrock R, Shtalrid M, Talpaz M, Kloetzer WS, Gutterman JU. Expression of c-abl in Philadelphia-positive acute myelogenous leukemia. Blood. 1987; 70:1584-1588.
• [3]Sweet K, Zhang L, Pinilla-Ibarz J. Biomarkers for determining the prognosis in chronic myelogenous leukemia. J Hematol Oncol. 2013; 6:54. BioMed Central Full Text
• [4]Ahmed W, Van Etten RA. Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond. Hematology Am Soc Hematol Educ Program. 2013; 2013:189-200.
• [5]Kantarjian HM, Talpaz M, Giles F, O’Brien S, Cortes J. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med. 2006; 145:913-923.
• [6]Ravandi F. Managing Philadelphia chromosome-positive acute lymphoblastic leukemia: role of tyrosine kinase inhibitors. Clin Lymphoma Myeloma Leuk. 2011; 11:198-203.
• [7]Lü S, Wang J. Homoharringtonine and omacetaxine for myeloid hematological malignancies. J Hematol Oncol. 2014; 7:2. BioMed Central Full Text
• [8]Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I et al.. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012; 367:2075-2088.
• [9]Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE et al.. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011; 378:1931-1939.
• [10]Smith AD, Roda D, Yap TA. Strategies for modern biomarker and drug development in oncology. J Hematol Oncol. 2014; 7:70. BioMed Central Full Text
• [11]Pemovska T, Johnson E, Kontro M, Repasky GA, Chen J, Wells P et al.. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation. Nature. 2015; 519:102-105.
• [12]Okabe S, Tauchi T, Tanaka Y, Katagiri S, Kitahara T, Ohyashiki K. Activity of omacetaxine mepesuccinate against ponatinib-resistant BCR-ABL-positive cells. Blood. 2013; 122:3086-3088.